5th INTERNATIONAL FORUM ON MOOD AND ANXIETY DISORDERS

Scientific Programme
WEDNESDAY, November 9, 2005

16.00 – 18.00

**S01 - SUICIDE OVERVIEW**
Chair: L. Pezawas (Austria) - J. Zohar (Israel)

**S0101 - Predictors and prevention of suicide**
J. Angst (Switzerland)

**S0102 - Suicide and antidepressants**
J. Sinclair (United Kingdom)

**S0103 - Toxicity of antidepressants in overdose**
R. Frey (Austria)

**S0104 - Suicidality and mortality in PTSD**
J. Zohar (Israel)

18.00 – 20.00

**S02 - IS THERE A TREATMENT FOR RECURRENT BRIEF DEPRESSION?**
Chair: J. Angst (Switzerland) - R. Frey (Austria)

**S0201 - Diagnostic issues**
H. Løvdahl (Norway)

**S0202 - Epidemiology**
J. Angst (Switzerland)

**S0203 - Genetic influence on mood circuitries**
L. Pezawas (Austria)

**S0204 - Treatment**
S. Kasper (Austria)

20.00 – 20.30

Opening Reception – Welcome Cocktail
THURSDAY, November 10, 2005

08.30 – 10.30

S03 - ARE THERE SUPERIOR ANTIDEPRESSANTS?
Chair: P. Delgado (USA) - S. Montgomery (United Kingdom)

S0301 - Focus on Escitalopram
R. Nil (Switzerland)

S0302 - Focus on Venlafaxine
R. Entsuah (USA)

S0303 - Focus on Milnacipran
F. Denis (France)

S0304 - Focus on Mirtazapine
A. Szegedi (The Netherlands)

10.30 – 10.45  Coffee Break & Poster Session

10.45 – 12.45

S04 - NEW ANTIDEPRESSANTS
HOW DO THEY WORK AND HOW EFFECTIVE ARE THEY?
Chair: S. Montgomery (United Kingdom)

S0401 - What can we learn from pre-clinical studies of antidepressants?
P. Blier (Canada)

S0402 - Escitalopram vs. the SSRI citalopram - results from a randomised head-to-head study
N. Moore (France)

S0403 - Are antidepressants equally effective in severe depression?
S. Montgomery (United Kingdom)

S0404 - Time to antidepressive effect - which antidepressant works best?
S. Kasper (Austria)

Sponsored by an unrestricted educational grant of H. LUNDBECK A/S

12.45 – 13.45  Lunch
13.45 – 15.45

**S05 - SEXUALITY**
Chair: D. S. Baldwin (United Kingdom) - M. D. Waldinger (The Netherlands)

*S0501* - Sexual dysfunction with antidepressants
D. S. Baldwin (United Kingdom)

*S0502* - Is there a way to improve sexual dysfunction in depression?
A. Tölk (Austria)

*S0503* - Differential impairment of sexual dysfunction with antidepressants
A. L. Montejo Gonzalez (Spain)

*S0504* - Drug treatment of premature ejaculation
M. D. Waldinger (The Netherlands)

15.45 – 16.00  Coffee Break & Poster Session

16.00 – 18.00

**S06 - SNRIs ALL FOR ONE AND ONE FOR ALL?**
Chair: S. Kasper (Austria)

*S0601* - SNRIs Fruit of a logical evolution of antidepressant action
S. Montgomery (United Kingdom)

*S0602* - SNRIs a new generation of treatment for anxiety disorders
D. S. Baldwin (United Kingdom)

*S0603* - SNRIs new hope in the treatment of chronic pain
P. Delgado (USA)

*S0604* - SNRIs Vive la différence
P. Blier (Canada)

Sponsored by an unrestricted educational grant of PIERRE FABRE MEDICAMENT

18.00 – 20.00

**S07 - TREATMENT UPDATE IN GAD**
Chair: M. Lader (United Kingdom), M. de Zwaan (Germany)

*S0701* - Escitalopram in the anxiety disorders
M. Lader (United Kingdom)

*S0702* - Pregabalin: a new pharmacological tool for the treatment of GAD
C. Altamura (Italy)

*S0703* - A critical review of CBT in GAD
M. de Zwaan (Germany)

*S0704* - Is there an algorithm for treatment of GAD?
B. Bandelow (Germany)
FRIDAY, November 11, 2005

08.30 – 10.30

**S08 - ANTIDEPRESSANTS AND PAIN**

Chair: C. Altamura (Italy), M. Briley (France)

- **S0801** - Fibromyalgia and antidepressants
  M. Briley (France)

- **S0802** - Duloxetine and the control of pain
  M. Detke (USA)

- **S0803** - SSRIs and painful symptoms in depression
  H. Agren (Sweden)

- **S0804** - Pregabalin and the treatment of neuropathic pain
  T. K. Murphy (USA)

10.30 – 10.45  **Coffee Break & Poster Session**

10.45 – 12.45

**S09 - DIAGNOSIS AND TREATMENT OF DEMENTIA**

Chair: C. K. Broich (Germany), Sampaio (Portugal)

- **S0901** - Brain-imaging diagnostic and outcome markers in Alzheimer's disease - ready as surrogate parameters?
  K. Broich (Germany)

- **S0902** - Designs for demonstrating efficacy in Age Associated Memory Impairment (AAMI)
  G. Dunbar (USA)

- **S0903** - Obstacles in demonstrating efficacy in Minimal Cognitive Impairment (MCI)
  C. Sampaio (Portugal)

- **S0904** - New strategies in the treatment of BPSD in dementia
  D. Kunz (Germany)

12.45 – 13.45  **Lunch**
13.45 – 15.45

S10 - NEW INSIGHTS IN TREATMENT RESISTANT DEPRESSION (TRD)
Chair: E. Seifritz (Switzerland), D. Souery (Belgium)

S1001 - Diagnosis and definition
Y. Lecrubier (France)

S1002 - European program on TRD
D. Souery (Belgium)

S1003 - Molecular basis of TRD
H. Aschauer (Austria)

S1004 - Brain mechanisms of TRD
E. Seifritz (Switzerland)

15.45 – 16.00  Coffee Break & Poster Session

16.00 – 18.00

S11 - LONG-TERM TREATMENT OF BIPOLAR DISORDER
Chair: J. Cookson (United Kingdom), T. Schläpfer (Germany)

S1101 - Are atypicals mood stabilizers?
H. Grunze (Germany)

S1102 - Antidepressants in bipolar depression
J. Cookson (United Kingdom)

S1103 - Brain stimulation for depression
T. Schläpfer (Germany)

S1104 - Suicidality
A. Erfurth (Austria)

18.00 – 18.15

CLOSURE
P01. MCM-H II personality profile of depressive patients. A.E. Afkham1,2,3, M. Salehi1,2,4, B. Daneshamouz1,2,4 (‘Iran University of Medical Sciences, Tehran Institute of Psychiatry, Rasoul Akram Hospital, 4Iran Psychiatric Center, Iran).

P02. Escitalopram for relapse prevention in generalised anxiety disorder. C. Allgulander1, A. Huusom2, I. Florea2 (‘Karolinska Institutet, Sweden, Neurotec Department, Section of Psychiatry, 3H. Lundbeck A/S, Denmark).

P03. Is the nutritional pattern of school children with attention deficit/hyperactivity disorder different from normal subjects? R. Amani1, N. Khaje-Mogushi2 (‘Dept. of Nutrition, Alvaz Jundi Shapour University of Med. Sciences, 2Golestan Hospital, Iran).


P05. Sertraline in the treatment of patients with depression and psoriasis. L.M. Bardenshteyn1, Y.I. Voronina2 (‘Moscow State University of Medicine and Dentistry, Department of Psychiatry and Nacology, 2Moscow State University of Medicine and Dentistry, Department of Dermatology and Venereology, Moscow, Russia).

P06. Results of a Spanish nationwide cross-sectional study on major depression IV: relationship between somatic symptoms, quality of life and resource utilization. L. Caballero1, E. Aragonés2, J. García-Campayo3, F. Rodríguez-Artalejo4, J. L. Ayuso-Mateos5, M. J. Polavieja6, E. Gómez-Uteroa6, I. Romera5, I. Gilaberte6 (‘Puerta de Hierro Hospital, 2Constantí primary health care center, 3Miguel Servet Hospital, 4Universidad Autónoma de Madrid, 5La Princesa Hospital, 6Clinical research department, Lilly Spain, Spain).

P07. Results of a Spanish nationwide cross-sectional study on major depression in primary care III: relationship between somatic symptoms and severity of depression. L. Caballero1, E. Aragonés2, J. García-Campayo3, F. Rodríguez-Artalejo4, J. L. Ayuso-Mateos5, M.J. Polavieja6, E Gómez-Utero6, I. Romera6, I. Gilaberte6 (‘Puerta de Hierro Hospital, 2Constantí primary health Care Center, 3Miguel Servet Hospital, 4Universidad Autónoma de Madrid, 5La Princesa Hospital, 6Clinical research department, Lilly Spain, Spain).

P08. Results of a Spanish nationwide cross-sectional study on major depression in primary care II: prevalence and factors related to somatization disorder. L. Caballero1, E. Aragonés2, J. García-Campayo3, F. Rodríguez-Artalejo4, J. L. Ayuso-Mateos5, M.J. Polavieja6, E. Gómez-Uteroa6, I. Romera5, I. Gilaberte6 (‘Puerta de Hierro Hospital, 2Constantí primary health care center, 3Miguel Servet Hospital, 4Universidad Autónoma de Madrid, 5La Princesa Hospital, 6Clinical research department, Lilly Spain, Spain).

P09. Results of a Spanish nationwide cross-sectional study on major depression in primary care I: prevalence and characteristics of somatic symptoms. L. Caballero1, E. Aragonés2, J. García-Campayo3, F. Rodríguez-Artalejo4, J. L. Ayuso-Mateos5, M.J. Polavieja6, E. Gómez-Uteroa6, I. Romera5, I. Gilaberte6 (‘Puerta de Hierro Hospital, 2Constantí primary health care center, 3Miguel Servet Hospital, 4Universidad Autónoma de Madrid, 5La Princesa Hospital, 6Clinical research department, Lilly Spain, Spain).

P10. Pilot study of clonazepam and milnacipran in the treatment of patients with panic disorder with comorbid major depression. A.H. Cia1, J.A. Brizuela1, E. Cascardo1, M.F. Varela1 (‘Clinica Moravia, Buenos Aires, Argentina).


P16. Modafinil as an adjunct treatment to sleep deprivation in depression. C. Even', J. Thuile', J.D. Guelfi', P. Bourgin' ('Clinique des maladies mentales et de l’encephale, Centre Hospitalier Sainte-Anne, Université René Descartes Paris-V, France, 'Stanford University School of Medicine, Department of Psychiatry and Behavioral Sciences, Center for Narcolepsy Research, USA).


P24. Neuropsychological correlations of symptom dimensions of obsessive-compulsive disorder. T.H. Ha1, J.S. Kwon1, K.S. Ha1 (Department of Psychiatry, Seoul National University College of Medicine, Korea).

P25. Analysis of relation between time management behaviors and occupational stress of medical surgical wards. H. Hashemizadeh1, S. KH Hoviat Thalab2 (Ghoochan Azad Islamic University, 2Shaheed Beheshti Medical University, Iran).

P26. Onset of action of escitalopram: results of a pooled analysis. S. Kasper1, C. Spadone2, P. Verpillat3, J. Angst4 (1Department of General Psychiatry, Medical University of Vienna, Austria 2Hôpital Saint-Louis, 3H. Lundbeck A/S, France, 4Zurich University Psychiatric Hospital, Switzerland).

P27. A pooled analysis of selective serotonin reuptake inhibitors (SSRIs) and venlafaxine. S.H. Kennedy1, H.F. Andersen2, R. Nil2, R.W. Lam3 (1University Health Network, University of Toronto, Canada, 2H. Lundbeck A/S, Switzerland, 3University of British Columbia, Canada).

P28. Frontal dysfunction underlies depressive syndrome in Alzheimer’s disease: a fdg-PET study. D.Y. Lee1,2, I.H. Choo1, J.H. Hoo2, K.W. Kim3, J.C. Youn3, D.S. Lee6, E.J. Kang7, J.S. Lee6, W.J. Kang6, J.I. Woo1 (1Department of Neuropsychiatry and Clinical Research Institute, Seoul National University Hospital, 2Interdisciplinary Program of Cognitive Science, Seoul National University, 3Department of Psychiatry, Pundang Jesaeng Hospital, Daejin Medical Center, Seongnam, 4Department of Neuropsychiatry, Seoul National University Bundang hospital, Seongnam, 5Department of Neuropsychiatry, Kyunggi Provincial Hospital for the Elderly, Yongin, 6Department of nuclear medicine, Seoul National University Hospital, 7Department of Psychology, College of Social Science, Kangwon National University, 8Neuroscience Research Institute of the Medical Research Center, Seoul National University, Korea).

P29. Seasonality associated with the serotonin 2A receptor polymorphism. H.J. Lee1, S.M. Sung1, L. Kim1 (Department of Psychiatry, Korea University College of Medicine, Korea).

P30. Interpersonal group psychotherapy in bipolar out-patients. M. Martin1, A. Fernandez-Cuevas1 (Hospital Universitario Gregorio Marañon, Spain).

P31. Anxiety and mood disorders in children with learning disabilities. A. Michopoulou1, V. Goula1, S.M. Papatheodorou1, G. Stefanou1, D. Giannios1, A. Nikolaou1, R. Athanasiadou1, A. Iliadou1, K. Voikli1, B. Belessioti1 (1Penteli’s Children Hospital, Palea Penteli, Greece).


P33. Discontinuation-emergent symptoms of duloxetine treatment in patients with major depressive disorder. D. Perahia1,2, D. Kajdasz3, D. Desai1,3, P. Haddad4 (1Lilly Research Centre, USA, 2The Gordon Hospital, 3Lilly Research Laboratories, 4University of Manchester, UK).

P34. Seasonal birth distribution in healthy siblings of melancholic and atypical SAD patients. E. Pjrek1, D. Winkler1, A. Konstantinidis1, J. Stavn1, N. Praschak-Rieder2, M. Willeit2, S. Kasper1 (1Department of General Psychiatry, Medical University of Vienna, Austria, 2Centre of Addiction and Mental Health, Toronto, Canada).

P35. Compliance with-weekly fluoxetine vs daily-fluoxetine and other selective serotonin reuptake inhibitors after the maintenance therapy in major depressive disorder. I. Romero1, S. López1, J. Árbesu2, V. Gasull3, J. Garrate3, I. Gilaberte1 (1Clinical Research Department,
Lilly Spain, 3Primary Health Care Center Paseo Extremadura, 3Primary Health Care Center Sama de Langreo, 4Primary Health Care Center Aldaia, 5Primary Health Care Center Espartero, Spain).

P36. Vulnerability to psychosis increases the risk of depression. R. K. R. Salokangas1,2,3, S. Luutonen1,2, M. Nieminen1, J. Huttunen1, H. Karlsson4 (1Department of Psychiatry, University of Turku, 2Psychiatric Clinic, Turku University Central Hospital, 3Turku Psychiatric Clinic, Turku Mental Health Centre, 4Department of Psychiatry, University of Helsinki, Finland).

P37. PET neuroimaging of [11c]mirtazapine antidepressant sites in humans and [11c]mirtazapine enantiomers in pigs. K. Smith1,3, D. F. jako1,2, S. Marthibsen1, D. Bender1, S.B. Hansen1, B. Smith2, F. Hermansen1, R. Rosenberg2, P. Cumming1 (1PET Center, Aarhus, University Hospital, Aarhus C, 2Center for Basic Psychiatric Research, Psychiatric Hospital, Risskov, Denmark, 3Hungarian Academy of Sciences, Research Group of Technical Analytical Chemistry, Budapest, Hungary).

P38. The measurement of anxiety in depression. L. Stefanovic1, M. Munjiza1 (1Institute for Mental Health, Belgrade, Serbia).

P39. Escitalopram and GAD: efficacy across different subgroups and outcomes. D. Stein1, R. Nil2, H.F. Andersen2, W.K. Goodman3 (1IMRC Unit on Anxiety Disorders, University of Stellenbosch, South Africa, 2H. Lundbeck A/S, Switzerland, 3University of Florida, USA).

P40. Onset of action of quetiapine monotherapy in bipolar mania. E. Vieta1, B. Paulsson2, J. Mullen3, M. Brecher3 (1Hospital clinic, Idibaps, University of Barcelona, 2Astrazeneca, 3Astrazeneca).


P42. Hypersomnia in atypical seasonal depression – a comparison between objective measurements and subjective reports. D. Winkler1, E. Pjrek1, J. Stastny1, A. Konstantinidis2, N. Praschak-Rieder2, M. Willeit2, S.Kasper1 (1Department of General Psychiatry, Medical University of Vienna, Austria, 2Centre of Addiction and Mental Health, Toronto, Canada).